国产BD管线“比肩”明星口服环肽,数十亿美元分子来了?

盖德化工网
Jan 08

生物制剂成为一线主流治疗方案且持续迭代的市场,小分子与口服多肽凭借毫不逊色的“临床治愈”疗效,用药成本更低,依从性更好,预计也将跑出数十亿美元“明星分子”。图源:pexels中重度银屑病高比例“临床治愈”,国产BD管线“比肩”明星口服环肽Guide View近日,Alumis公司下一代口服TYK2 抑制剂 Envudeucitinib(从中国海思科引进)在两项针对中重度斑块状银屑病的关键III 期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10